NO2119726T3 - - Google Patents

Info

Publication number
NO2119726T3
NO2119726T3 NO08008944A NO08008944A NO2119726T3 NO 2119726 T3 NO2119726 T3 NO 2119726T3 NO 08008944 A NO08008944 A NO 08008944A NO 08008944 A NO08008944 A NO 08008944A NO 2119726 T3 NO2119726 T3 NO 2119726T3
Authority
NO
Norway
Application number
NO08008944A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39789337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2119726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2119726T3 publication Critical patent/NO2119726T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO08008944A 2008-05-14 2008-05-14 NO2119726T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08008944.4A EP2119726B2 (en) 2008-05-14 2008-05-14 Novel and powerful MHC-class II peptides derived from survivin and neurocan

Publications (1)

Publication Number Publication Date
NO2119726T3 true NO2119726T3 (pl) 2015-05-23

Family

ID=39789337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08008944A NO2119726T3 (pl) 2008-05-14 2008-05-14

Country Status (24)

Country Link
US (5) US8647629B2 (pl)
EP (3) EP2119726B2 (pl)
JP (1) JP5663473B2 (pl)
KR (2) KR101602024B1 (pl)
CN (1) CN102027006B (pl)
AU (1) AU2009248413B2 (pl)
BR (2) BRPI0912622A2 (pl)
CA (1) CA2724198C (pl)
CY (2) CY1115999T1 (pl)
DK (2) DK2119726T5 (pl)
EA (1) EA019603B1 (pl)
ES (2) ES2532896T5 (pl)
HK (2) HK1156323A1 (pl)
HR (2) HRP20150300T4 (pl)
HU (2) HUE024541T2 (pl)
MX (1) MX2010012443A (pl)
NO (1) NO2119726T3 (pl)
NZ (1) NZ588605A (pl)
PL (2) PL2119726T5 (pl)
PT (2) PT2119726E (pl)
RS (1) RS53872B2 (pl)
SI (2) SI2119726T2 (pl)
UA (1) UA103481C2 (pl)
WO (1) WO2009138236A1 (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
SI2567707T1 (sl) * 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
PT2113253E (pt) * 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
NO2119726T3 (pl) * 2008-05-14 2015-05-23
DK2512450T3 (en) * 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012023033A2 (en) * 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
KR20130126671A (ko) * 2010-12-14 2013-11-20 이매틱스 바이오테크놀로지스 게엠베하 전립선 관련 항원 분자로부터 유래된 hla 결합 펩티드 및 이의 사용방법
CN102181401B (zh) * 2011-02-01 2013-04-24 北京市肿瘤防治研究所 存活素酶联免疫试剂盒及其应用
KR20140100419A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
WO2015066057A2 (en) * 2013-10-28 2015-05-07 Baylor College Of Medicine Expansion of cmv-specific t cells from cmv-seronegative donors
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
PT3388075T (pt) * 2015-03-27 2023-08-18 Immatics Biotechnologies Gmbh Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
IL308735A (en) * 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MY198087A (en) * 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
PE20230343A1 (es) * 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
MX2019000180A (es) * 2016-06-28 2019-11-05 Geneius Biotechnology Inc Composiciones de células t para la inmunoterapia.
JP7346291B2 (ja) 2016-09-21 2023-09-19 アマル セラピューティクス エスエー 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
AR110857A1 (es) 2017-01-27 2019-05-08 Immatics Biotechnologies Gmbh Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
SG11201906198PA (en) 2017-01-27 2019-08-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA47683A (fr) 2017-03-03 2020-01-08 Treos Bio Zrt Plate-forme d'identification de peptide immunogène reposant sur une population
WO2019007974A1 (en) * 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
WO2019072871A2 (en) 2017-10-09 2019-04-18 Enterome S.A. MICROBIOTIC SEQUENCE VARIANTS OF ANTIGENIC EPITOPES ASSOCIATED WITH A TUMOR
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US20210113678A1 (en) 2018-04-11 2021-04-22 Enterome S.A. Antigenic Peptides For Prevention And Treatment Of Cancer
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
CN112399970A (zh) * 2018-05-15 2021-02-23 英特肽治疗有限公司 肽活化剂
US20210380639A1 (en) * 2018-05-15 2021-12-09 Interk Peptide Therapeutics Limited Activating Agents
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
HUE065075T2 (hu) 2019-11-15 2024-04-28 Enterome S A Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére
BR112022020376A2 (pt) * 2020-04-14 2022-11-22 Univ Montreal Antígenos específicos de tumor para leucemia mieloide aguda (lma) e usos dos mesmos
CA3215344A1 (en) * 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023021056A1 (en) * 2021-08-17 2023-02-23 Intomics A/S Vaccine design pipeline
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FI86437C (fi) 1978-12-22 1992-08-25 Biogen Inc Foerfarande foer framstaellning av polypeptider med de antigena egenskaperna hos ett hepatitis b- virusantigen.
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
PT879282E (pt) 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6255055B1 (en) * 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US6274362B1 (en) * 1999-02-04 2001-08-14 Millennium Pharmaceuticals, Inc. RGS-containing molecules and uses thereof
WO2001072768A2 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2005512249A (ja) 2001-12-13 2005-04-28 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ メディアシステム上のメディアコンテンツの推薦
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
CN1691964A (zh) * 2002-09-06 2005-11-02 曼康公司 表位序列
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1714157A2 (en) * 2004-01-28 2006-10-25 Immatics Biotechnologies GmbH Method for identifying and quantifying of tumour-associated peptides
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
PT1806358E (pt) 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
ATE440107T1 (de) 2005-09-05 2009-09-15 Immatics Biotechnologies Gmbh Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
CA2629113A1 (en) † 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
SI2567707T1 (sl) * 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
PT2113253E (pt) * 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
NO2119726T3 (pl) * 2008-05-14 2015-05-23
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer

Also Published As

Publication number Publication date
KR101509284B1 (ko) 2015-04-10
DK2291395T3 (da) 2015-09-21
EP2119726B1 (en) 2014-12-24
ES2549088T5 (es) 2019-04-29
US20130323272A1 (en) 2013-12-05
AU2009248413B2 (en) 2014-07-17
EP2119726B2 (en) 2017-11-29
PL2291395T5 (pl) 2019-04-30
PT2291395E (pt) 2015-10-23
CY1115999T1 (el) 2017-01-25
PL2119726T3 (pl) 2015-05-29
SI2291395T1 (sl) 2015-10-30
EP2899206A1 (en) 2015-07-29
US9498512B2 (en) 2016-11-22
BR122019014468B8 (pt) 2021-07-27
US20140086943A1 (en) 2014-03-27
ES2532896T5 (es) 2018-03-20
CN102027006B (zh) 2016-01-13
EA201071297A1 (ru) 2011-04-29
SI2291395T2 (sl) 2019-03-29
CA2724198C (en) 2016-03-22
ES2549088T3 (es) 2015-10-22
KR20130041375A (ko) 2013-04-24
PL2291395T3 (pl) 2016-01-29
JP2011520436A (ja) 2011-07-21
HUE028102T2 (en) 2016-11-28
ES2532896T3 (es) 2015-04-01
HUE024541T2 (hu) 2016-01-28
SI2119726T1 (sl) 2015-05-29
AU2009248413A1 (en) 2009-11-19
DK2119726T3 (en) 2015-02-16
EP2291395B1 (en) 2015-08-12
NZ588605A (en) 2012-06-29
HRP20150300T1 (hr) 2015-04-24
KR20110021881A (ko) 2011-03-04
EA019603B1 (ru) 2014-04-30
SI2119726T2 (en) 2018-03-30
PL2119726T5 (pl) 2018-04-30
HK1209757A1 (en) 2016-04-08
US20200078439A1 (en) 2020-03-12
JP5663473B2 (ja) 2015-02-04
CY1117171T1 (el) 2017-04-05
DK2291395T4 (en) 2019-02-18
RS53872B2 (sr) 2018-06-29
BR122019014468B1 (pt) 2020-09-15
KR101602024B1 (ko) 2016-03-09
RS53872B1 (en) 2015-08-31
US20100029571A1 (en) 2010-02-04
DK2119726T4 (en) 2018-02-19
US8647629B2 (en) 2014-02-11
EP2291395A1 (en) 2011-03-09
BRPI0912622A2 (pt) 2016-05-03
US11957729B2 (en) 2024-04-16
PT2119726E (pt) 2015-03-30
CA2724198A1 (en) 2009-11-19
DK2119726T5 (en) 2018-03-26
US20140127242A1 (en) 2014-05-08
HRP20151135T4 (hr) 2019-03-08
HRP20151135T1 (hr) 2015-11-20
HK1156323A1 (en) 2012-06-08
CN102027006A (zh) 2011-04-20
HRP20150300T4 (hr) 2018-03-09
WO2009138236A1 (en) 2009-11-19
UA103481C2 (ru) 2013-10-25
US10434136B2 (en) 2019-10-08
EP2119726A1 (en) 2009-11-18
MX2010012443A (es) 2010-12-20
EP2291395B2 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
BRPI0917573A2 (pl)
BRPI0918697A2 (pl)
BRPI0917525A2 (pl)
BRPI0920750A2 (pl)
NO2119726T3 (pl)
BRPI0919470A2 (pl)
BRPI0922455A2 (pl)
BRPI0917618A8 (pl)
BRPI0907698A2 (pl)
BRPI0923734A2 (pl)
BRPI0912727A2 (pl)
BRPI0910485A2 (pl)
BRPI0914750A2 (pl)
BRPI0912462A2 (pl)
BRPI0915616A2 (pl)
BRPI0919811A2 (pl)
BRPI0920914A2 (pl)
BRPI0922550A2 (pl)
BRPI0916284A2 (pl)
BRPI0913605A2 (pl)
BRPI0911617A2 (pl)
BRPI0914852A2 (pl)
BRPI0910572A2 (pl)
CH2347250H2 (pl)
BRPI0914820A2 (pl)